Results 191 to 200 of about 3,018,020 (304)

Noncanonical amino acids enable plug and play vaccine platform in the ALiCE cell free system. [PDF]

open access: yesNPJ Vaccines
Armero-Gimenez J   +10 more
europepmc   +1 more source

Engineering Biology Beyond Single Genes: Advances and Challenges in Multiplex Genome Editing

open access: yesAnimal Research and One Health, EarlyView.
Multiplex genome editing is transforming genome engineering from single‐gene perturbation to network‐level control, yet its broader application remains limited by challenges in gRNA array engineering, delivery technologies, and safety management. Emerging AI‐driven approaches are accelerating guide RNA design and CRISPR effector optimization for ...
Linli Wang, Yongbin Liu, Hongbing Han
wiley   +1 more source

Manganese Mineralization of Pathogenic Viruses as a Universal Vaccine Platform. [PDF]

open access: yesAdv Sci (Weinh), 2023
Shi PD   +10 more
europepmc   +1 more source

At the Interface: How Bat, Swine, and Bovine Reservoir Networks Shape Coronavirus Emergence in Human Populations

open access: yesAnimal Research and One Health, EarlyView.
Coronavirus spillover is driven by interacting bat, swine, and bovine reservoir networks rather than isolated host species. A One Health framework reveals critical surveillance gaps and identifies livestock‐associated monitoring as a practical frontline strategy for preventing future zoonotic emergence.
Ahmed H. Ghonaim   +12 more
wiley   +1 more source

Pharmacokinetics, Effectiveness and Safety of Certolizumab Pegol in Children and Adolescents With Active Juvenile Idiopathic Arthritis: 9+‐Year Results From a Multicenter, Open‐Label Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The purpose of this study was to assess the pharmacokinetics, effectiveness, safety, and immunogenicity of certolizumab pegol (CZP) in polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods Pediatric Arthritis Study of Certolizumab Pegol (NCT01550003), a multicenter, open‐label study, enrolled patients aged 2 to 17 years with ...
Hermine I. Brunner   +52 more
wiley   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy